Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents

Leukemia and Lymphoma

Volumn 20, Issue 1-2, 1995, Pages 67-76

  Wu, A G ^a   Joshi, S S ^a   Chan, W C ^a   Iversen, P L ^a   Jackson, J D ^a   Kessinger, A ^a,b   Pirruccello, S J ^a   Sanger, W G ^a   Sharp, J G ^a   Verbik, D J ^a   Whalen, V L ^a   Bishop, M R ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Autologous stem cell transplant; B2A2; B3A2; Bcr abl; Ex vivo purging agent

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN;

ARTICLE; CELL STRAIN K 562; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT GM; CONTROLLED STUDY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BASE SEQUENCE; BONE MARROW PURGING; CELL DIVISION; CELL LINE; COLONY-FORMING UNITS ASSAY; DNA PRIMERS; EXONS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; HEMATOPOIETIC STEM CELLS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES, ANTISENSE; POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIONUCLEOTIDES; TUMOR CELLS, CULTURED;

EID: 0029588277     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199509054755     Document Type: Article

References (34)

1. A minute chromosome in human chronic granulocytic leukemia
2. Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22
3. The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene
4. Relationship between the location of the breakpoint within MBCR and clinical parameters
5. In vitro transformation of immature hematopoietic cells by the p210 bcrlabl oncogene product of the Philadelphia chromosome
6. Induction of chronic myelogenous leukemia by the p210 bcrlabl gene of the Philadelphia chromosome
7. Structural organization of bcr gene and its role in the ph translocation
8. Parental origin of chromosome involved in the t(9;22)
9. Intensive treatment in order to minimize the ph-positive clone in chronic myelogenic leukemia
10. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2
11. Normal and hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging
12. Selective inhibition of leukemia cell proliferation by bcrlabl antisense oligodeoxynucleotides
13. In vitro culture of clonogenic leukemic cells in acute myeloid leukemia: growth pattern and drug sensitivity
14. Autologous transplantation of blood derived hemopoietic stem cells after myeloablation therapy in a patient with Burkitt's lymphoma
15. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocytic-macrophage colony-stimulating factor
16. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
17. Lack of reciprocal translocation in BCR-ABL positive ph negative chronic myeloid leukemia
18. Identification of masked and variant ph (complex type) translocation in CKL and classic ph in AML and ALL by fluorescence in situ hybridization with the use of bcr-abl cosmid probes
19. Antisense inhibition of group II phospholipase A2 expression blocks the production of prostaglandin E2 by P38D1 cells
20. Protein kinase C isotype in human erythroleukemia (K562) cell proliferation and differentiation. Evidence that beta II protein kinase C is required for proliferation
21. Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides
22. Nucleolar and nuclear aberration in human lox tumor cells following treatment with p120 antisense oligonucleotide ISIS-3466
23. Depletion of casein kinase II by antisense oligonucleotide prevents neuritogenesis in neuroblastoma cells
24. In vivo modulation of N-mye expression by continuous perfusion with an antisense oligonucleotide
25. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligonucleotides
26. Potential therapeutic application of antisense oligonucleotides in the treatment of chronic myelogenous leukemia
27. In vivo treatment of human leukemia in a scid model with c-myb antisense oligonucleotides
28. 1 leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotide
29. Electroporation of lymphoma cells with c-myc antisense oligonucleotides. A model for bone marrow purging. Abstract
30. Minimal residual disease after bone marrow transplant for chronic myeloid leukemia detected by the polymerase chain reaction
31. What does one do for the CML patient in relapse after allogeneic bone marrow transplantation?
32. Autografting for patients with chronic myeloid leukemia—the Hammersmith experience
33. Intensive treatment in order to minimize the ph- positive clone in chronic myelogenic leukemia
34. In vitro toxicological evaluation of ISIS-1082, a phosphorothioate oligonucleotide inhibitor of herpes simplex virus